Infect Chemother.  2018 Sep;50(3):266-267. 10.3947/ic.2018.50.3.266.

Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”

• Kim T
• Lee SO

• KMID: 2420911
• DOI: http://doi.org/10.3947/ic.2018.50.3.266

Abstract

No abstract available.

MeSH Terms

Bronchoalveolar Lavage Fluid*
Bronchoalveolar Lavage*
Lymphocytes*
Pneumocystis jirovecii*
Pneumocystis*
Risk Factors*

Reference

1. Kim T, Sung H, Chong YP, Kim SH, Choo EJ, Choi SH, Kim TH, Woo JH, Kim YS, Lee SO. Low lymphocyte proportion in bronchoalveolar lavage fluid as a risk factor associated with the change from trimethoprim/sulfamethoxazole used as first-line treatment for Pneumocystis jirovecii pneumonia. Infect Chemother. 2018; 50:110–119. PMID: 29968978.

2. Smego RA Jr, Nagar S, Maloba B, Popara M. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch Intern Med. 2001; 161:1529–1533. PMID: 11427101.

3. Armstrong-James D, Copas AJ, Walzer PD, Edwards SG, Miller RF. A prognostic scoring tool for identification of patients at high and low risk of death from HIV-associated Pneumocystis jirovecii pneumonia. Int J STD AIDS. 2011; 22:628–634. PMID: 22096046.

4. Kim T, Moon SM, Sung H, Kim MN, Kim SH, Choi SH, Jeong JY, Woo JH, Kim YS, Lee SO. Outcomes of non-HIV-infected patients with Pneumocystis pneumonia and concomitant pulmonary cytomegalovirus infection. Scand J Infect Dis. 2012; 44:670–677. PMID: 22264016.